Matches 1 - 50 out of 78 1 2 >


Match Document Document Title
8183354 Virus coat protein/receptor chimeras and methods of use  
The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor....
7667006 Anti-HIV antibody  
The present invention aims at providing a high affinity anti-HIV antibody. According to the present invention, there are provided an antibody or a fragment thereof that binds to the gp12...
7625566 Anti-idiotypic monoclonal antibody reactive with HIV neutralizing antibody 2F5  
The invention relates to Ab2-type anti-idiotypic antibodies and fragments thereof which mimic HVI-1 epitopes that are otherwise cryptic to the immune system and which antibodies or fragments...
7595049 IGG1 monoclonal antibody with anti-HIV neutralizing activity  
The present invention relates to neutralizing anti-HIV-1 antibodies, particularly to mAb 4E10-IgG1, which has an HIV-1 neutralizing potency comparable to the one of mAb 2F5 and 2G12. 4E10-IgG1...
7442550 Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein  
A method for detecting the expression of a polypeptide in cells and for detecting the interaction between a polypeptide and cells, ex vivo or in vitro, wherein the polypeptide is selected from the...
7223844 Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by Env-CD4-co-receptor complexes  
The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4,...
7056735 Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator)  
The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane...
7041293 HIV env antibodies  
The invention provides antibodies specific for HIV env, including monoclonal antibodies and related hybridomas. The antibodies block CD4/g120 binding and reduce reverse transcriptase activity in...
6949337 Cellular receptor for HIV-1 Vpr essential for G2/M phase transition of the cell cycle  
The present invention provides methods of identifying anti-HIV compound by contacting human Vpr Interacting Protein (hVIP), or a fragment thereof known to interact with Vpr, with Vpr, or a fragment...
6927023 Method of identifying modulators of HIV-1 Vpu and Gag interaction with U binding protein (Ubp)  
A preparation of U binding protein (Ubp) and a gene sequence encoding Ubp and an anti-Ubp antibody are disclosed. An assay to identify modulators of Ubp/Vpu interaction and Gag/Ubp interaction is...
6908734 Sulfated CCR5 peptides for HIV-1 infection  
This invention provides a compound comprising the structure: θαYDINYYTSEβλ wherein each T represents a threonine, each S represents a serine, each E represents a glutamic acid, each Y rep...
6893813 Methods for treatment of HIV and other infections using a T cell or viral activator and anti-retroviral combination therapy  
Disclosed is a method for treating infection with a pathogen. The method involves administration of: (1) a substance which induces active pathogen replication in a cell latently infected with HIV...
6821744 Method, assay, and kit for quantifying HIV protease inhibitors  
A method for quantifying an HIV protease inhibitor in a sample includes combining HIV protease, a conjugate comprising an HIV protease inhibitor analog, and a sample suspected of containing an HIV...
6821723 GP41 antigen  
The present invention comprises novel polypeptide antigens that can be used for therapeutic and prophylactic immunization against HIV-related infections. The polypeptide of the invention mimics the...
6818392 Monoclonal antibodies to human immunodeficiency virus and uses thereof  
The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of...
6815201 HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies  
The invention features a protein which includes a gp120 V1/V2 domain of an HIV-1 strain and not a gp120 V3 domain of an HIV-1 strain, which protein does not substantially bind CD4. The gp120 V1/V2...
6812026 Antibodies directed against binding-associated epitopes  
Binding of two members of a binding couple reveal epitopes which are revealed only after binding and the monoclonal antibody secreted from the hybridoma cell line CG-10 directed against these...
6812025 Two hybrid assay that detects HIV-1 reverse transcriptase dimerization  
This invention provides methods of determining whether a compound inhibits HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound inhibits formation of a...
6783939 Alphavirus vectors and virosomes with modified HIV genes for use in vaccines  
The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic...
6733993 Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications  
First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described...
6709811 Versatile reagent for detecting murine leukemia viruses  
A method for detecting broad spectrum of murine leukemia viruses belonging to any or all of the ecotropic, xenotropic, polytropic and amphotropic groups, has been described. The method utilizes a...
6703019 Cationized antibodies against intracellular proteins  
The subject application discloses methods and compositions for the targeted detection and/or inhibition of an intracellular protein in a cell by contacting the cell with a cationized antibody which...
6696291 Synthetic HIV gag genes  
Synthetic DNA molecules encoding HIV gag and modifications of HIV gag are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules...
6670181 Compositions and methods for treating viral infections  
Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization...
6670466 Human endogenous retrovirus in breast cancer  
The present invention is related to mammary tumor virus (MTV). MTV represents a group of retroviruses which possess very high homology to mouse mammary tumor virus (MMTV), a virus known to cause...
6653130 Method for the development of an HIV vaccine  
Human immunodeficiency virus (HIV) comprising reverse transcriptase inactivated by photoinactivation used to evoke an immune response. The immune response may protect an individual from challenges...
6649409 Method for producing a nucleotide sequence construct with optimized codons for an HIV genetic vaccine based on a primary, early HIV isolate and synthetic envelope BX08 constructs  
The present invention relates to a method for producing a nucleotide sequence construct with optimized codons for an HIV genetic vaccine based on a primary, early HIV isolate. Specific such...
6605427 Assay for detection of viral fusion inhibitors  
The invention is directed to a methods for identifying compounds that inhibit or prevent infection of cells by enveloped viruses such as HIV-1 by preventing or disrupting conformational changes in...
6479284 Humanized antibody and uses thereof  
A humanized antibody framework motif is described. Preferably, the motif is encoded by the VH gene of K5B8 and the VL gene of TR1.6. This humanized antibody preferably contains the variable region...
6465173 Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease  
The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with...
6448375 Active and inactive CC-chemokine receptor  
A peptide has an amino acid sequence having more than 80% homology with the amino acid sequence listed as SEQ ID NO:4. A nucleic acid molecule has more than 80% homology with one of the nucleic...
6432714 Prophylactic and therapeutic method  
Antigenic and/or immunoregulatory material derived from Mycobacterium vaccae is useful in the prophylaxis or therapy of AIDS with or without associated tuberculosis.
6406911 Compositions and methods for sensitive detection of HIV infection and monitoring of drug resistance  
A method is provided for detecting a presence of HIV virus in a sample comprising: taking a culture of recombinant cells which (a) are capable of cell division, (b) express CD4 receptor and one or...
6403300 Monoclonal antibodies for detection of friend murine leukemia virus  
The present invention relates to Friend murine leukemia virus (F-MuLV) specific monoclonal antibodies, or binding fragments thereof, specific for an antigenic determinant of a gp85 envelope...
6379957 Methods for HIV sequencing and genotyping  
Methods are provided for amplifying regions of the HIV pol gene amplifying double-stranded nucleic acid template derived from HIV tube RT-PCR with novel PCR primers to produce amplified target...
6365404 Hematopoietic cell method for treatment of HIV infection  
The risk of drug resistance in HIV infection is reduced by profoundly suppressing the viral load using novel hematopoietic cells. Modified CD4 lymphocyte host cells are used to “capture” virons in ...
6333163 Method of facilitating HIV-1 infection through human leukotriene B4 receptor  
The present invention provides a human leukotriene B4 receptor that acts as a coreceptor for HIV viruses, polynucleotides encoding the receptor, recombinant cells expressing the receptor, and...
6309880 Antibodies specific for CD4-binding domain of HIV-1  
A particular epitope located within the CD4-binding region of gpl20 of HIV-1, and antibodies specific for the epitope which can inhibit HIV-1 infection of human cells by diverse strains and...
6291239 Monoclonal antibody  
A monoclonal antibody (FE8) against human complement receptor type 2 CR2, CD21) which is able to substantially remove C3-derived fragments already attached to CR2, in particular C3dg from CR2 at...
6287568 Methods relating to immunogenic dextran-protein conjugates  
This invention includes the conception of T-independent conjugate-vaccines and its application in the induction of antigen specific IgA response. We demonstrated that 1) α(1,6)dextran can elicit a ...
6284536 Modified immunoglobin molecules and methods for use thereof  
Disclosed are modified immunoglobulin (Ig) molecules, a method of producing modified Ig molecules, and methods for treatment and prevention of infectious diseases using modified Ig molecules. In...
6277561 Diagnostic assay for detection of HIV  
A novel immunodeficiency virus is disclosed which has the designation MVP-5180/91 and which has been deposited with the European Collection of Animal Cell Cultures (ECACC) under No. V 920 92 318....
6268484 HIV-vaccines  
Disclosed are antibodies which can be used for the manufacture of vaccines for active and/or passive immunization of persons in need of such treatment. The invention also provides for human...
6221580 Anti-idiotypic and its uses in diagnosis and therapy in HIV-related disease  
The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with...
6197583 Therapeutic compounds  
The invention relates to a biologically-active peptide fragment of the Nef protein of human immunodeficiency virus, to pharmaceutical compositions comprising these peptides or biologically-active...
6168923 Compositions and methods for use of IL-12 as an adjuvant  
Improved vaccine compositions and methods of making same are provided, which vaccines are characterized by an antigen from a pathogen and an effective adjuvanting amount of Interleukin-12. These...
6140043 Pharmaceutical compositions for competitively inhibiting the binding of a retrovirus to the IFN-receptor and means for diagnosis of an HIV infection  
The present invention is based on the observation that HIV does not only interact with the CD4 receptor of target cells but that there exists a different type of interaction between HIV envelope...
6124132 Use of anti-HIV IGA antibodies for producing immunological protection against the human immunodeficiency virus  
The subject invention concerns the production and novel use of human anti-HIV IgA antibodies to confer passive immunity to HIV when administered in vivo to a subject. The IgA antibodies of the...
RE36866 Anti-aids immunotoxins  
The present invention provides a novel anti-AIDS immunotoxin. The immunotoxin comprises a toxin chemically conjugated to a monoclonal antibody directed against viral reverse transcriptase. Also...
6030772 Neutralizing antibodies against HIV infection  
Neutralizing antibodies against HIV infection are provided. The antibodies are reactive with cryptic epitopes on gp120 and/or CD4 induced by the formation of immunogenic complexes comprising gp120...
Matches 1 - 50 out of 78 1 2 >